Initial context for Immunome stock

Immunome (IMNM) has attracted fresh attention after recent share price swings, with the stock now around US$22.19 and a market value near US$2.64b. This has prompted investors to reassess how current fundamentals line up with expectations.

Recent trading has been choppy, with a 1 day share price return of a 4.64% decline and a 7 day share price return of a 3.27% decline. However, the 1 year total shareholder return of 187.81% and 3 year total shareholder return of about 2.5x suggest momentum has been strong over a longer stretch.

If Immunome has caught your eye, it could be worth widening the search to other oncology and biotech opportunities with AI exposure using our screener of 35 healthcare AI stocks

With Immunome trading around US$22.19 against an average analyst price target near US$35.54 and an intrinsic value estimate suggesting a wide gap, you have to ask: is there mispricing here, or is the market already baking in future growth?

Preferred Price-to-Book of 4x: Is it justified?

Immunome trades on a P/B of 4x, which sits above the broader US biotech industry average of 2.5x, so the stock is priced at a premium to that group.

The P/B ratio compares the market value of the equity to its book value. This can be useful for early stage or loss-making biotechs where earnings-based multiples are less helpful. A higher P/B often reflects expectations for future value creation rather than current profitability.

For Immunome, a 4x P/B suggests investors are placing meaningful value on its pipeline of oncology assets and forecast revenue growth, even though the company is currently loss-making and forecast to remain unprofitable over the next 3 years. Relative to peers, the stock looks expensive versus the broader biotech industry but more in line with a closer peer set where the average P/B is 4.1x. This indicates the market is not assigning an outlier premium within that group.

That premium sits alongside a very different signal from the SWS DCF model, which values the stock at $180.09 per share compared with the last close of $22.19. This indicates a large gap between a cash flow based estimate and current trading levels. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 4x (OVERVALUED)

However, strong DCF upside arguments face real risks, including Immunome's current net loss of US$212.394m and its reliance on a small revenue base of US$6.941m.

Another way to look at value: SWS DCF model

While the 4x P/B ratio presents Immunome as expensive versus the wider biotech group, the SWS DCF model points the other way. In this view, an estimated fair value of $180.09 per share, compared with the recent $22.19 price, indicates a wide gap between these two valuation perspectives. How comfortable are you with such a difference between these signals?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Immunome for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of strong past returns, premium valuation signals and DCF upside can feel conflicting, so it makes sense to review the underlying data and act while the picture is still fresh. To see both the concerns and potential upsides in one place, it is worth checking the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Immunome is on your radar, do not stop there. Broaden your watchlist now so you are not late to the next opportunity.

• Spot potential mispricings early by scanning 51 high quality undervalued stocks that combine quality fundamentals with appealing prices.
• Prioritise resilience by reviewing 72 resilient stocks with low risk scores that score well on stability and downside protection.
• Hunt for future standouts by checking the screener containing 23 high quality undiscovered gems before they get crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.